Connor Clark & Lunn Investment Management Ltd. Acquires 26,096 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 59.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 70,037 shares of the company's stock after purchasing an additional 26,096 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.06% of Vaxcyte worth $8,003,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in PCVX. Riverview Trust Co bought a new stake in Vaxcyte during the 3rd quarter worth about $27,000. Fifth Third Bancorp acquired a new position in Vaxcyte during the second quarter valued at approximately $35,000. Blue Trust Inc. grew its stake in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after purchasing an additional 93 shares in the last quarter. J.Safra Asset Management Corp increased its position in shares of Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after purchasing an additional 526 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Vaxcyte during the 2nd quarter worth approximately $70,000. Institutional investors own 96.78% of the company's stock.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the firm's stock in a transaction on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the transaction, the chief financial officer now owns 90,383 shares in the company, valued at $10,429,294.37. This trade represents a 31.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Grant Pickering sold 2,366 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total value of $245,803.74. Following the sale, the chief executive officer now owns 137,398 shares of the company's stock, valued at approximately $14,274,278.22. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 102,464 shares of company stock valued at $11,455,576. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Trading Up 0.2 %

PCVX stock traded up $0.15 during mid-day trading on Friday, hitting $88.54. 1,614,295 shares of the company were exchanged, compared to its average volume of 1,610,634. Vaxcyte, Inc. has a 1-year low of $48.24 and a 1-year high of $121.06. The stock has a market capitalization of $11.04 billion, a PE ratio of -19.25 and a beta of 1.01. The business has a 50 day simple moving average of $107.89 and a 200-day simple moving average of $89.41.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period last year, the firm earned ($0.91) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on PCVX shares. Bank of America raised their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Needham & Company LLC reissued a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Jefferies Financial Group raised their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Leerink Partners lifted their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a report on Tuesday, September 3rd. Finally, BTIG Research upped their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte currently has a consensus rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.